FibroGen, Inc. (FGEN) Analysts See $-0.27 EPS; AURA SYSTEMS (AUSI) Shorts Up By 17.78% – The EN Herald

Analysts expect FibroGen, Inc. (NASDAQ:FGEN) to report $-0.27 EPS on August, 6.They anticipate $0.01 EPS change or 3.57% from last quarter’s $-0.28 EPS. After having $-0.53 EPS previously, FibroGen, Inc.’s analysts see -49.06% EPS growth. The stock decreased 0.07% or $0.03 during the last trading session, reaching $44.35. About 480,035 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has declined 23.86% since July 3, 2018 and is downtrending. It has underperformed by 28.29% the S&P500. Some Historical FGEN News: 12/04/2018 – $GLPG moving fast into #IPF Ph3 vs. $FGEN still at a snail’s pace; 09/05/2018 – FibroGen 1Q Loss/Shr 50c; 31/05/2018 – ASTELLAS PHARMA INC – ROXADUSTAT WAS WELL TOLERATED IN STUDY; 21/05/2018 – FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018; 13/03/2018 Announcing The First Andes Summit – Indigenous Wisdom-Keepers to Gather With People of The North to lnitiate a New Commitment to Earth Healing; 18/04/2018 – The Andes Summit: More Than Ayahuasca – A Re-Validation of the Cultural Heritage of Ecuador’s Ancient Indigenous Wisdom; 25/04/2018 – $GSK catching up quickly in HIF vs. $FGEN and $AKBA Positive results in house from first of three Ph3 for daprodustat in Japan; 12/04/2018 – ARGENTINA IS SAID TO PROBE TRADES OF ANDES FOR INSIDER TRADING; 21/05/2018 – FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic; 07/05/2018 – RESOURCE CAPITAL FUND Vl L.P. ANNOUNCES ACQUISITION OF UNITS IN LOS ANDES COPPER LTD

AURA SYSTEMS INC (OTCMKTS:AUSI) had an increase of 17.78% in short interest. AUSI’s SI was 5,300 shares in July as released by FINRA. Its up 17.78% from 4,500 shares previously. With 8,300 avg volume, 1 days are for AURA SYSTEMS INC (OTCMKTS:AUSI)’s short sellers to cover AUSI’s short positions. It closed at $0.18 lastly. It is up 0.00% since July 3, 2018 and is . It has underperformed by 4.43% the S&P500.

Aura Systems, Inc., a mobile power company, designs, assembles, and sells axial flux induction machines. The company has market cap of $9.38 million. The firm offers patented mobile power solutions, including AuraGen, an axially symmetric induction machine for electric motors and generators; VIPER , an axial flux induction generator for military applications, such as homeland security and coast guard; and transport refrigeration systems. It currently has negative earnings. The Company’s products are also used in telecommunications, utilities, emergency rescue, catering, public works, and gas and oil industries.

More notable recent FibroGen, Inc. (NASDAQ:FGEN) news were published by: Finance.Yahoo.com which released: “Here’s What Hedge Funds Think About FibroGen Inc (FGEN) – Yahoo Finance” on June 13, 2019, also Nasdaq.com with their article: “Notable Wednesday Option Activity: FIZZ, LEN, FGEN – Nasdaq” published on June 19, 2019, Globenewswire.com published: “FibroGen Appoints Suzanne Blaug to Board of Directors – GlobeNewswire” on June 05, 2019. More interesting news about FibroGen, Inc. (NASDAQ:FGEN) were released by: Globenewswire.com and their article: “FibroGen to Present Interim Phase 2 Data on Pamrevlumab in Subjects with Duchenne Muscular Dystrophy at the Parent Project Muscular Dystrophy 2019 Annual Conference – GlobeNewswire” published on June 28, 2019 as well as Finance.Yahoo.com‘s news article titled: “The Week Ahead In Biotech: Pending Clinical Readouts In Focus – Yahoo Finance” with publication date: June 29, 2019.

Among 4 analysts covering FibroGen (NASDAQ:FGEN), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. FibroGen had 7 analyst reports since February 11, 2019 according to SRatingsIntel. The company was maintained on Thursday, February 28 by Jefferies. Mizuho maintained FibroGen, Inc. (NASDAQ:FGEN) on Thursday, February 28 with “Buy” rating. The firm earned “Buy” rating on Monday, February 11 by Stifel Nicolaus.

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $3.70 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It currently has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.